Evidence map›Paper›PMID 36033707›Full record

ArticleACS omega2022

Exploring Highly Functionalized Tetrahydropyridine as a Dual Inhibitor of Monoamine Oxidase A and B: Synthesis, Structural Analysis, Single Crystal XRD, Supramolecular Assembly Exploration by Hirshfeld Surface Analysis, and Computational Studies.

Bilal Ahmad Khan, Muhammad Ashfaq, Shabbir Muhammad, Khurram Shahzad Munawar, Muhammad Nawaz Tahir, Abdullah G Al-Sehemi, Saleh S Alarfaji

Abstract read
In one paragraph

Article in ACS omega, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Bilal Ahmad KhanDepartment of Chemistry, University of Azad Jammu and Kashmir, Muzaffarabad 13100, Azad Jammu and Kashmir, Pakistan.ORCID https://orcid.org/0000-0002-7648-7359
Muhammad AshfaqDepartment of Physics, University of Sargodha, Sargodha, Punjab 40100, Pakistan.ORCID https://orcid.org/0000-0001-6663-8777
Shabbir MuhammadDepartment of Chemistry, College of Science, King Khalid University, P.O. Box 9004, Abha 61413, Saudi Arabia.ORCID https://orcid.org/0000-0003-4908-3313
Khurram Shahzad MunawarInstitute of Chemistry, University of Sargodha, Sargodha 40100, Pakistan.ORCID https://orcid.org/0000-0001-9055-2519
Muhammad Nawaz TahirDepartment of Physics, University of Sargodha, Sargodha, Punjab 40100, Pakistan.
Abdullah G Al-SehemiDepartment of Chemistry, College of Science, King Khalid University, P.O. Box 9004, Abha 61413, Saudi Arabia.ORCID https://orcid.org/0000-0002-6793-3038
Saleh S AlarfajiDepartment of Chemistry, College of Science, King Khalid University, P.O. Box 9004, Abha 61413, Saudi Arabia.ORCID https://orcid.org/0000-0001-7297-7185

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ethyl 4-(4-fluorophenylamino)-2,6-bis(4-(trifluoromethyl)phenyl)-1-(4-fluoro-phenyl)-1,2,5,6-tetrahydropyridine-3-carboxylate (

Identifiers

PMID36033707
PMCPMC9404513

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.